Literature DB >> 21965757

Case report of pneumatosis intestinalis secondary to sunitinib treatment for refractory gastrointestinal stromal tumor.

Anthony Jarkowski1, Ryan Hare, Valerie Francescutti, Neal Wilkinson, Nikhil Khushalani.   

Abstract

Pneumatosis intestinalis (PI) occurs when inter-luminal air enters the bowel wall of the gastrointestinal tract via a mucosal defect. The condition is caused by numerous disease states, direct trauma, and various drugs. When PI is secondary to drug therapy, discontinuation of the offending agent results in the resolution of PI. We report on the case of a 73-year-old male with a history of refractory gastrointestinal stromal tumor experiencing PI while on sunitinib treatment. PI was noted via computed tomography (CT) scans 68 days after starting sunitinib therapy and showed near complete resolution on a follow up CT performed one month after discontinuing sunitinib. Given that a CT scan performed five months prior to the initiation of sunitinib did not show PI, lack of abdominal symptoms in our patient, and resolution of PI after discontinuing sunitinib, the cause of PI in our patient was likely due to sunitinib treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21965757

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

Review 1.  What the emergency radiologist needs to know about treatment-related complications from conventional chemotherapy and newer molecular targeted agents.

Authors:  Sona A Chikarmane; Bharti Khurana; Katherine M Krajewski; Atul B Shinagare; Stephanie Howard; Aaron Sodickson; Jyothi Jagannathan; Nikhil Ramaiya
Journal:  Emerg Radiol       Date:  2012-06-07

Review 2.  Pneumatosis intestinalis during chemotherapy with nilotinib in a patient with chronic myeloid leukemia who tested positive for anti-topoisomerase I antibodies.

Authors:  Akihito Fujimi; Hiroki Sakamoto; Yuji Kanisawa; Shinya Minami; Yasuhiro Nagamachi; Naofumi Yamauchi; Soushi Ibata; Junji Kato
Journal:  Clin J Gastroenterol       Date:  2016-09-16

Review 3.  Pneumatosis cystoides intestinalis associated with sunitinib and a literature review.

Authors:  Yong Suk Lee; Jae Joon Han; Si-Young Kim; Chi Hoon Maeng
Journal:  BMC Cancer       Date:  2017-11-09       Impact factor: 4.430

4.  Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.

Authors:  Hironori Uruga; Shuhei Moriguchi; Yui Takahashi; Kazumasa Ogawa; Kyoko Murase; Sayaka Mochizuki; Shigeo Hanada; Hisashi Takaya; Atsushi Miyamoto; Nasa Morokawa; Kazuma Kishi
Journal:  BMC Cancer       Date:  2018-08-16       Impact factor: 4.430

Review 5.  Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review.

Authors:  Gianluca Gazzaniga; Federica Villa; Federica Tosi; Elio Gregory Pizzutilo; Stefano Colla; Stefano D'Onghia; Giusy Di Sanza; Giulia Fornasier; Michele Gringeri; Maria Victoria Lucatelli; Giulia Mosini; Arianna Pani; Salvatore Siena; Francesco Scaglione; Andrea Sartore-Bianchi
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

6.  Pneumatosis Cystoides Intestinalis Secondary to Sunitinib Treatment for Gastrointestinal Stromal Tumor.

Authors:  Yoh Asahi; Takuto Suzuki; Akiufumi Sawada; Masaya Kina; Joji Takada; Hiroko Gotoda; Hiroyuki Masuko
Journal:  Case Rep Gastroenterol       Date:  2018-08-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.